EcoR1 Capital’s Janux Therapeutics JANX Stock Holding History

EcoR1 Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,469,818	Closed	-$34M	–	36
2025 Q2	$34M	Hold	1,469,818	–	–	2.01%	12
2025 Q1	$39.7M	Hold	1,469,818	–	–	2.35%	11
2024 Q4	$78.7M	Hold	1,469,818	–	–	2.98%	11
2024 Q3	$66.8M	Hold	1,469,818	–	–	2.29%	11
2024 Q2	$61.6M	Buy	+1,469,818	New	+$69M	1.88%	15
2023 Q3	–	Sell	-452,590	Closed	-$5.37M	–	55
2023 Q2	$5.37M	Sell	452,590 -3,385,896	-88%	-$45.3M	0.13%	38
2023 Q1	$46.4M	Buy	3,838,486 +2,417,167	+170%	+$40.2M	1.5%	15
2022 Q4	$18.7M	Hold	1,421,319	–	–	0.57%	30
2022 Q3	$19.2M	Hold	1,421,319	–	–	0.57%	28
2022 Q2	$17.4M	Hold	1,421,319	–	–	0.6%	30
2022 Q1	$20.4M	Buy	1,421,319 +9,344	+0.7%	+$153K	0.64%	30
2021 Q4	$27.9M	Hold	1,411,975	–	–	0.89%	23
2021 Q3	$30.5M	Hold	1,411,975	–	–	1.06%	18
2021 Q2	$35.2M	Buy	+1,411,975	New	+$31.4M	1.32%	16

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EcoR1 Capital's JANX Position: Q3 2025 in Review

EcoR1 Capital sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 1,469,818 shares — an estimated $34M sold.

EcoR1 Capital first reported a position in JANX in Q2 2021 and held it in 14 quarters. The position peaked at $78.7M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

EcoR1 Capital reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
EcoR1 Capital sold 1,469,818 Janux Therapeutics shares in Q3 2025, an estimated $34M.
EcoR1 Capital first reported a position in Janux Therapeutics in Q2 2021 and held it in 14 quarters.
EcoR1 Capital's Janux Therapeutics position peaked at $78.7M in Q4 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.